In terms of immunomodulatory treatments, omalizumab has been approved in the USA for management of IgE‐mediated food allergy in children from 1 year of age and adults; and oral allergen‐specific immunotherapy can be recommended for peanut, egg and milk allergies. The gene discussed is IGHE; the disease is food allergy.